In the last 50 years, there have been great research and developments in the definition and pathophysiology of acute respiratory distress syndrome (ARDS), the most progressive form of acute hypoxemic respiratory failure. Although there are various discussions and recommendations, the definition of ARDS is still based on the Berlin 2012 diagnostic criteria. Despite various studies in recent years, there is still no effective pharmacotherapeutic agent for the treatment of ARDS. Lung protective mechanical ventilation (low tidal volume, low plateau pressure, low driving pressure) in all ARDS patients, prone position, neuromuscular blockade (cisatracurium) in moderate-severe ARDS patients, and hydrocortisone therapy in sepsis-associated ARDS patients are treatments that contribute to survival. In this review, current changes in the definition and epidemiology of ARDS, recent pharmacotherapeutic research and mesenchymal stem cell therapies will be discussed in the light of newly introduced ARDS phenotypes.

Download full-text PDF

Source
http://dx.doi.org/10.5578/tt.20219611DOI Listing

Publication Analysis

Top Keywords

ards patients
12
ards
9
current situation
4
situation ards
4
ards light
4
light studies
4
studies classification
4
classification epidemiology
4
epidemiology pharmacotherapeutics
4
pharmacotherapeutics years
4

Similar Publications

Background: 22q11 deletion syndrome consists of a variable grouping of phenotypic features and immunological defects secondary to the loss of genetic material located in the 22q11.2 band. The 22q11 deletion spectrum encompasses different syndromes related to the same etiology and with overlapping anomalies, including DiGeorge syndrome, velocardiofacial syndrome, among others.

View Article and Find Full Text PDF

Objective: The objective of this study is to present the clinical characteristics of immunoglobulin G4-related diseases (IgG4-RD) patients and describe associated overlap with autoimmune rheumatic diseases (ARDs).

Patients And Methods: This cross-sectional study included 81 patients with IgG4-RD who were recruited from 13 specialized rheumatology departments and centers across the country in collaboration with the Egyptian College of Rheumatology (ECR). Patients underwent a thorough history-taking and clinical examination.

View Article and Find Full Text PDF

Only a few studies have examined the effects of coronavirus disease 2019 (COVID-19) and influenza on clinical outcomes in pediatric patients. Furthermore, no meta-analysis has assessed the impact of these diseases on adverse outcomes. This study aims to compare the clinical outcomes of COVID-19 and influenza in pediatric patients.

View Article and Find Full Text PDF

Objectives: To investigate the serum surfactant protein D (SP-D) level required to determine the diagnosis and prognosis of coronavirus disease 2019 (COVID-19), and create a new scale for disease prognosis prediction.

Methods: This study was conducted among 64 patients with COVID-19 symptoms and 16 healthy volunteers. The participants were assessed by comparing "Controls/Patients", "PCR-negative/PCR-positive", "Simple COVID-19/Acute respiratory distress syndrome (ARDS)-accompanied COVID-19", "Mild ARDS/Moderate-severe ARDS", and "Survived/Dead" subgroups.

View Article and Find Full Text PDF

Background: In recent times, the applications of continuous renal replacement therapy (CRRT) beyond kidney-related conditions have been progressively increasing, and its implementation in randomized controlled trials (RCTs) specifically for acute respiratory distress syndrome (ARDS) has been documented. This meta-analysis compiles all existing RCTs to assess whether CRRT benefits ARDS.

Methods: We searched 12 databases in English and Chinese and two clinical trial centers up to November 28, 2023.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!